Compounds > 11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid
Page last updated: 2024-09-02

11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid and raclopride

11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid has been researched along with raclopride in 1 studies

Compound Research Comparison

Studies
(11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid)		Trials
(11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid)		Recent Studies (post-2010)
(11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid)		Studies
(raclopride)		Trials
(raclopride)		Recent Studies (post-2010) (raclopride)
304271031,802132419

Protein Interaction Comparison

ProteinTaxonomy11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid (IC50)raclopride (IC50)
D(2) dopamine receptorHomo sapiens (human)0.052
D(2) dopamine receptorMus musculus (house mouse)0.032
D(2) dopamine receptorRattus norvegicus (Norway rat)0.0279

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Boellaard, R; Bossong, MG; Kahn, RS; Lammertsma, AA; Ramsey, NF; Schuit, RC; van Berckel, BN; van Gerven, JM; Windhorst, AD; Zuurman, L1

Trials

1 trial(s) available for 11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid and raclopride

ArticleYear
Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2009, Volume: 34, Issue:3

    Topics: Administration, Inhalation; Adult; Cannabinoid Receptor Modulators; Corpus Striatum; Cross-Over Studies; Dopamine; Double-Blind Method; Dronabinol; Heart Rate; Humans; Magnetic Resonance Imaging; Male; Placebos; Positron-Emission Tomography; Psychiatric Status Rating Scales; Raclopride; Receptors, Dopamine D2; Receptors, Dopamine D3

2009